Antisense Therapeutics has been granted a patent for a method to treat multiple sclerosis, including progressive forms, by administering OLIGONUCLEOTIDE I. The method involves detecting active brain lesions through MRI imaging and administering a pharmaceutical composition containing the oligonucleotide. GlobalData’s report on Antisense Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Antisense Therapeutics Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Antisense Therapeutics, Nucleic acid active pharmaceutical ingredient was a key innovation area identified from patents. Antisense Therapeutics's grant share as of February 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11891606B2) outlines a method for treating multiple sclerosis (MS) in human subjects with active brain lesions detectable by MRI. The method involves imaging the subject to detect new active brain lesions and administering a pharmaceutical composition containing a specific oligonucleotide. The administration of this composition aims to inhibit brain volume change, atrophy, or disability progression in the treated individual.

Furthermore, the patent details specific dosages, administration frequencies, and additional therapeutic agents that can be used in conjunction with the oligonucleotide treatment. The method also specifies the form of MS that can be treated, including relapsing forms like relapsing-remitting MS (RRMS) or progressive forms. The pharmaceutical composition can be administered subcutaneously and is designed to reduce the number of active brain lesions detectable by MRI, ultimately improving the condition of individuals with MS. The patent provides a comprehensive guide for healthcare professionals looking to utilize this method for treating MS patients with active brain lesions.

To know more about GlobalData’s detailed insights on Antisense Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies